TriangleZEN003694 (NCT05607108)
ZEN003694 trial for Squamous Cell Lung Cancer (NCT05607108). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent or metastatic squamous-cell lung cancer showing NSD3 gain or amplification. Previous platinum chemotherapy and immunotherapy are required, together or in sequence.
The idea: test ZEN003694, which blocks BET proteins that may support NSD3-driven tumor growth. Everyone takes sixty milligrams orally daily for five days, followed by two days off, in twenty-one-day cycles. Researchers measure tumor responses. Previous experimental BET-inhibitor treatment excludes participation.
This phase 2 study plans 13 patients. Paul Paik leads Memorial Sloan Kettering's study, with seven recruiting US locations; one offers limited protocol activities.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.